Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 crossover study of CNSA-001 versus Kuvan in adults with phenylketonuria
ACTRN12618001031257Phase 2Completed
- Sponsor
- Censa Pharmaceuticals
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of sepiapterin in phenylketonuria (PKU) and hyperphenylalaninemia (HPA) (6 arms), sponsored by Censa Pharmaceuticals. Primary endpoint: Reduction in phenylalanine levels. Started Oct 2018; status: completed.
02
Drugs
sepiapterin
03
Conditions
phenylketonuria (PKU)hyperphenylalaninemia (HPA)
Beyond the preview
Go deeper on ACTRN12618001031257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618001031257.